TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Forearm vascular resistance (FVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Detection of acute HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hyaluronic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transforming growth factor‐β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects completing the studies
Endpoint domain: Adverse events/effects
Primary endpoint: CGI improvement scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decreased hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: global assessment favoring relaxin over placebo
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CDIP-58 total scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in the rate of sweat production at the forehead
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversion to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-day case fatality
Endpoint domain: Mortality/survival
Primary endpoint: 18-month survival
Endpoint domain: Mortality/survival
Primary endpoint: Tear film turnover (TT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Punctate staining severity (Pdc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgency of urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: frequency of urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Achievement of adequate relative dose intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sevoflurane plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: timing compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bronchial hyperreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of new skin sensitizations
Endpoint domain: Adverse events/effects
Primary endpoint: mean reduction in PLA grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinical presentation total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTOG total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in PUFA concentrations in platelet and atrial tissue membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in postoperative rise in IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Candida spp. biofilm growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Candida levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFU counts of C. glabrata
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CISS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete sclerosis at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of venous sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of primary stopcock lumen contamination
Endpoint domain: Adverse events/effects
Primary endpoint: Combined incidence of HCAIs and IV catheter-associated phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Combined nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimates of absolute myocardial perfusion and kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: interval free of local disease
Endpoint domain: Mortality/survival
Primary endpoint: Alveolar osteitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IND-VFQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental component summary score change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation between target CT number and measured CT number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone:cortisol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement or total regression of hepatic encephalopathy episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of the PSE index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG abnormalities and ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of hGH-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality Adjusted Life Year (QALY) gain from colorectal screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall diabetes problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lifestyle problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Day-to-day diabetes routine problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: infarct size assessed by measuring creatine kinase release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major adverse cardiac event at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: Pain response scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall diagnostic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesser somnolence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean decrease in central macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of pigment epithelial detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abortion duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: percentage of women undelivered at 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Airway insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for KLT over ETI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ratios of SBP, DBP and baPWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ratios for standing and self-care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sympathoexcitatory response (skin conductance, breathing rate, heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of impacted earwax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal carriage of Staphylococcus strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of VAP (Ventilator-Associated Pneumonia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ACR50/70 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in DAS28‐C‐reactive protein/erythrocyte sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of AMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the ANELT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IBTRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-month uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spherical equivalent within ±0.50 D at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in root surface debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HbA1c decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Confirmed hypoglycaemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximum plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC(t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(last) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement degree of summed defect scores (TDS) (BMIPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement degree of summed defect scores (TDS) (TF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta regional wall motion score (WMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac events (death or myocardial infarction)
Endpoint domain: Mortality/survival
Primary endpoint: total falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slip falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trip falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASQ fine-motor domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASQ personal-social domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WPPSI‐III processing-speed quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Omentin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: autonomic, motor, and self-regulation functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge mean scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cerebral infarction resulting in fatal outcome
Endpoint domain: Mortality/survival
Primary endpoint: Objective cure rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of exophthalmos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac sympathetic neuronal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4+ T-cell proliferative responses to insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of death after hospitalization for WHF or MI
Endpoint domain: Mortality/survival
Primary endpoint: SRRC score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of complications
Endpoint domain: Adverse events/effects
Primary endpoint: pain on stretch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall quality of life (IVI score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in daytime and nighttime heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of patients with endoscopic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dye spread into the TPVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rates for CFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: additional days at home
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean total homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complications experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge destination (home or rehabilitation)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apparent remacemide clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of remacemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma phenobarbitone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediator scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seated time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death/HF hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of small meals sales to large meals sales
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rocuronium infusion dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for facilitated recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of cannulation at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peripheral intravenous cannulation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24 hour urinary magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDH and survival relationship
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events related to CNS
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance at first clinical examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: wound dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incremental gain of QALYs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sirolimus Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sirolimus AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: motor evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hmax / Mmax ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global health status/Quality of Life (GHS/QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tumour response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' mean EO score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surgeons' mean EO rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HF mortality
Endpoint domain: Mortality/survival
Primary endpoint: non-CV mortality
Endpoint domain: Mortality/survival
Primary endpoint: recurrence of AFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of significant AF beyond 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complications in group II
Endpoint domain: Adverse events/effects
Primary endpoint: psychological benefits of exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Choice of surgical procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time from induction to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of uterine hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Inspiratory Pressure (Pmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal Expiratory Pressure (Pemax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: death/major disability
Endpoint domain: Mortality/survival
Primary endpoint: major disability
Endpoint domain: Mortality/survival
Primary endpoint: premotor reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OSP delay before muscle action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OSP rate of rise and peak latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in or discontinuation of PPI therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of late-acquired ISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of late-acquired ISA volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion detection sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ABC-C scale irritability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ABC-C scale hyperactivity/noncompliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of patients with any new stroke (ischemic or hemorrhage)
Endpoint domain: Mortality/survival
Primary endpoint: Continuation rates of DMPA‐SC injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with DMPA‐SC and pharmacy setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in OCD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving minimal OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Constant score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aEEG patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Congruence between perceived and theoretical knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: High contrast PR-VEP amplitude of P100-N75 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P100-N145 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P1-N2 amplitudes in M-VEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: V'O(2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean concentrations (GMCs) of IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delay in the need for FS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic absorption of 5‐ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine excretion of 5‐ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Locoregional recurrence (LRR) risk
Endpoint domain: Mortality/survival
Primary endpoint: sum of skinfolds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported sedentary screen time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 24-hour microtensile bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes